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The acute nature of energy failure ismanifested either by ametabolic crisis withweakness, sometimes associated
with respiratory failure, or by myoglobinuria. A typical disorder where permanent weakness occurs is
glycogenosis type II (GSDII or Pompe disease) both in infantile and late-onset forms, where respiratory insufﬁ-
ciency is manifested by a large number of cases. In GSDII the pathogenetic mechanism is still poorly understood,
and has to be attributedmore to structuralmuscle alterations, possibly in correlation tomacro-autophagy, rather
than to energetic failure. This review is focused on recent advances about GSDII and its treatment, and the most
recent notions about the management and treatment of other metabolic myopathies will be brieﬂy reviewed,
including glycogenosis type V (McArdle disease), glycogenosis type III (debrancher enzyme deﬁciency or Cori
disease), CPT-II deﬁciency, and ETF-dehydrogenase deﬁciency (also known as riboﬂavin-responsive multiple
acyl-CoA dehydrogenase deﬁciency or RR-MADD). The discovery of the genetic defect in ETF dehydrogenase
conﬁrms the etiology of this syndrome. Other metabolic myopathies with massive lipid storage and weakness
are carnitine deﬁciency, neutral lipid storage-myopathy (NLSD-M), besides RR-MADD. Enzyme replacement
therapy is presented with critical consideration and for each of the lipid storage disorders, representative cases
and their response to therapy is included. This article is part of a Special Issue entitled: Neuromuscular Diseases:
Pathology and Molecular Pathogenesis.
© 2014 Published by Elsevier B.V.1. Introduction
In the last few years the ﬁeld of metabolic myopathies has beneﬁted
by the advent of the ﬁrst causative treatment: enzyme replacement
therapy (ERT) for glycogenosis type II (GSDII) or Pompe disease. The
availability of ERT changed the natural history of the disease, not only
because of the efﬁcacy in modifying the natural course in children, but
also because of the increased interest that indirectly produced and led
to relevant knowledge on clinical features and retrospective course of
the disease, study of pathophysiology and autophagic mechanisms
and research on genotype–phenotype correlations, etc. Many questions
arose, and some of them are still unsolved. Unfortunately, the advances
in the therapy of other metabolic myopathies are still limited.2. Glycogen storage diseases
2.1. Glycogenosis type II (GSDII, acid maltase deﬁciency, Pompe disease)
Glycogenosis type II or acid maltase deﬁciency is an autosomal–
recessive disorder caused by the deﬁciency of the lysosomal enzymeuscular Diseases: Pathology andacid α-glucosidase (GAA), which catalyzes the hydrolysis of α-1,4
and α-1,6 links of glycogen. The enzyme deﬁciency leads to accumu-
lation of glycogen and disruption of tissue architecture in different
organs, especially the skeletal muscles, heart and liver. The continuum
spectrum of clinical phenotypes ranges from an infantile-onset rapidly
fatal form to a slowly progressive adult form [1,2]. As a general rule, a
lower residual enzymatic level is correlated with an earlier onset, faster
progression of the disease, and worst prognosis [3,4]. The classic
infantile-onset formpresents in the ﬁrst months of life with generalized
hypotonia and muscle weakness, severe cardiomegaly, feeding difﬁcul-
ties, failure to thrive, and respiratory failure. Untreated patients usually
die in the ﬁrst year of life due to progressive cardio-respiratory failure
[5]. In the juvenile forms symptoms appear between 2 and 5 years of
age, and cardiomyopathy is rarely seen. The late-onset GSDII is charac-
terized by progressive proximal and axialmuscleweakness that leads to
a progressive loss of motor function, to an altered posture and to the
alteration of normal patterns of movement [6]. Although many muta-
tions have been characterized, a common IVS1 mutation has been
described. Genetic testing and the blood spot enzymology testing
serve as diagnostic tests, although a conﬁrmatory muscle biopsy is
sometimes required. Diaphragmatic weakness and respiratory insufﬁ-
ciency are frequent. Cardiac involvement is rarely reported in adult
patients and, when present, is usually less severe than infantile and ju-
venile patients and is characterized by cardiac hypertrophy (involving
the left ventricular wall or the ventricular septum) and conduction
616 C. Angelini / Biochimica et Biophysica Acta 1852 (2015) 615–621abnormalities [7,8]. In untreated late-onset patients, muscle strength
and pulmonary function usually deteriorate over the years, leading to
wheelchair use and respiratory support in most of cases; it has been
demonstrated that untreated adult GSDII patients present an invariably
progressive disease, have higher mortality compared with the general
population, and present a poor quality of life [9,10]. The incidence of
the disease is still uncertain, and varies in different ethnical groups.
Histopathological features of Pompe disease are intriguing and
variable in the different phenotypic forms of the disease. The histopath-
ological hallmark of the disease is muscle ﬁber vacuolization. Most of
the infantile and childhood-onset forms typically exhibitﬁbers occupied
by huge vacuoles that contain basophilic amorphous PAS positive
materials. The diagnosis of the adult-onset form, however, is sometimes
challenging, because vacuoles may be present only in few ﬁbers. The
histopathological ﬁndings can be misdiagnosed as muscular dystrophy
or inﬂammatory myopathy. Acid phosphatase positive globular inclu-
sions can be found in a small proportion of patients with adult-onset
Pompe disease, and have been proposed as a hallmark of Pompe disease
and a useful diagnostic marker when typical vacuolated ﬁbers are
lacking [11].
2.1.1. Autophagy
Autophagy, the major degradation pathway for long-lived proteins
and organelles, is essential for cell homeostasis, and its dysfunction
has been linked to a number of muscle disorders that are typically char-
acterized by massive autophagic build-up, such as GSDII and Danon
disease. These features were also shown in a knockout mouse model
of GSDII, where the areas of cellular debris, seen predominantly in
type IIB myoﬁbers, were associated with resistance to ERT [12]. In pa-
tients, the enormous build-up, rather than the enlarged, glycogen-
ﬁlled lysosomes outside the autophagic regions, appears to cause the
muscle damage [13]. What is emerging from recent studies on GSDII
patients is that autophagy impairment contributes to disease progres-
sion and ﬁber atrophy [14]. A residual functional autophagic ﬂux has
been shown to be important also for efﬁcient uptake of the recombinant
GAA (rhGAA) and GAAmaturation. Indeed, most of the cellular trafﬁck-
ing, including endosomal trafﬁcking, needed for rhGAA uptake and
delivery to lysosomes, uses proteins that also participate in autophagy;
the autophagosome accumulation that characterizes GSDII might
sequester these factors. Thematuration steps of GAA, from the synthesis
of the immature protein in the endoplasmic reticulum to the ﬁnal
cleaved active protein in lysosomes, are complex and require a functional
system of vesicle trafﬁcking. These ﬁndings highlight the importance to
develop new drugs to restore the autophagic ﬂux in these patients, in
order to improve the uptake of rhGAA.
The ﬁrst effective approach to the ERT was the rhGAA (Myozyme)
derived fromhamster ovary cells. The treatmentwas soon demonstrated
to be effective in infantile patients in markedly reducing left ventricular
mass and improving cardiomyopathy, which are the hallmark of infan-
tile form and the primary cause of death of infant patients. Furthermore,
rhGAA treatment reduced the risk of death and of invasive ventilation,
compared with an untreated control group [15]. In contrast to the natu-
ral course of untreated patients, most of treated infants acquired motor
and functional skills and some patients remained ambulant at the age
of 11 years [16]. It was thought that ERT started early in life of infantile
patients would have led to a shift toward a juvenile or late-onset pheno-
type, but thiswas not the fact: these long term survivor infantile patients
present peculiar clinical characteristics (such as elongated face and
bulbar features) that might be due to the lack of penetrance of rhGAA
in the central nervous system (CNS) [17,18].
The slowly progressing nature of adult GSDII patients and the wide
variability of organ involvementmake it difﬁcult to establish in individ-
ual patients the prognosis, to predict the clinical evolution of the disease
and to deﬁne the impact of therapies, such as ERT. The only randomized
placebo-controlled study is the LOTS (Late Onset Treatment Study), in
which 90 patients between 10 and 70 years of age were treated withrhGAA (60 patients) or placebo (30 cases) for 18 months [19]. The
treatment improved walking distance measured with the 6-minute
walk test (6 MWT) of 65 m and stabilized pulmonary function in the
rhGAA group, as compared to the slight worsening of walked distance
and respiratory function observed in the placebo group. Once again, a
possible lack of penetrance of rhGAA in the CNS respiratory centers
can be a cause of scarce response of respiratory parameters. Other
open-label studies evidenced a rather variable course of neuromuscular
outcomes in adult-onset GSDII patients during long observational
periods of ERT, demonstrating a variable effect in prolonging walked
distance and respiratory function [7,20]. For a better evaluation of natu-
ral course and treatment efﬁcacy, many studies have been done to
deﬁne accurate quantitative outcomemeasures. Apart from themanual
muscle testing for muscle strength, the examination of patients usually
includes a series of functional tests, such as the 6 MWT, and the timed
tests, such as the GSGC score (Gait, climbing Stairs, Gowers' maneuver
and arise form a Chair), which was validated in the clinical follow-up
of GSDII cases [21], as well as in Duchenne dystrophy. The 6 MWT
is a useful measurement of functional endurance during prolonged
ambulation, which is widely used for non-wheelchair dependent
patients [7,19]. It can be used for patients of different stages of the
disease; it is well related to daily-life activities and very sensitive
to underline even small differences in the clinical course of treated
and untreated patients [21]. An increasing role in the evaluation of
muscle disease has been acquired by muscle MRI, a non-invasive
exam that can evaluate muscle mass and ﬁbro-fatty muscle degener-
ation, and, when associated with spectroscopic studies, it may mea-
sure glycogen content [22]. A difﬁcult issue is to deﬁne when there is
an improvement in respiratory parameters. The Italian group on
GSDII has followed a series of 28 patients in ventilator and observed
that after ERT, the patients decreased signiﬁcantly the number of
hours in ventilator (Figs. 1, 2). The analysis of clinical efﬁcacy in
adult patients [23] evidenced that the motor response is widely
variable in each patient. Furthermore, it is important to underline
that up to a third of patients do not show signiﬁcant improvement
during treatment, or even might present a worsening of motor and
respiratory function.
The identiﬁcation of the factors underlying this variability of clinical
response to ERT needs further investigation. The efﬁcacy of treatment
needs to be accurately studied in each patient. The cost of therapy is a
crucial problem, and in a recent future it will become even more
important for the National Health Institutions, now that more and
more rare diseases are becoming treatable with emerging therapies.
A debated issue is when to start and when to stop ERT. Recent
guidelines from the American Association of Neuromuscular and
Electrodiagnostic Medicine (AANEM) [24] recommend the beginning
of ERT in symptomatic patients who have proximal muscle weakness
detectable bymanual muscle testing or reduction in respiratory param-
eters. Patients who have no symptoms or objective signs should be
examined every 6 months with an evaluation of muscle strength and
pulmonary function, and ERT should be started at the earliest onset of
symptoms or objective signs. In fact, it is now known that early treat-
ment is crucial in order to obtain the best result of ERT, especially in
infants [25]. For severely affected patients, no randomized clinical trial
has provided evidence regarding the effectiveness of ERT, and the
available data are scarce and controversial [26]. The bi-weekly hospital-
ization for the enzyme infusions may have a high impact on daily life of
patients (limitation in movements, respiratory support, etc.). For all
these reasons, Cupler et al. [24] suggested that ERT should be adminis-
tered for at least 1 year to adult patients and later decisions regarding
the continuation of ERT should be made on a case-by-case basis. Con-
versely, no agreement has been so far reached in timing of possible
ERT interruption, since ERT is the only therapy that was demonstrated
effective in this disease. The AANEM guidelines suggested that, because
of the high variability of the natural course and response proved by the
mild differences that have been demonstrated after ERT, the treatment
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Fig. 1. GSDII patients ventilated, 1 patient stoppedovernight ventilation after ERT.
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should discuss with the patient whether to continue ERT or not. The
ongoing studies on identiﬁcation of non-responder patient categories
may help insurances and National Health Institutions in this decision.
Usually the best response is at the initial onset of therapy and the subse-
quent decline of motor performances is seen. The lack of response of
respiratory muscles needs further studies, exploring diaphragmatic
movements and central respiratory drive and fatigue.2.2. Glycogenosis type III (GSDIII, debrancher enzyme deﬁciency, Cori disease)
The clinical forms of the disease, ranging from infant age with hypo-
tonia to adult forms with distal weakness, include a predominantly he-
patic form (hepatomegaly, hypoglycemia, and hyper-triglyceridemia)
and a muscular form (myopathy and cardiomyopathy) [27,28]. The
glycogen structure is abnormal with short peripheral chains and is
called limit-dextrin. Usual recommendations include frequent meals,
high-carbohydrate and high protein intake and raw cornstarch or con-
tinuous feeding during the night, which prevent fasting hypoglycemia
but do not inﬂuence the course of cardiac and muscular manifestations
[29]. Recently, Valayannopoulos et al. [30] proposed an experimental
treatment to a two-month old infant with a severe familial form of
GSDIII complicated by severe cardiomyopathy, whose sister had died
of severe cardiomyopathy on standard nutritional protocol. The authorsp < 0.005  
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Fig. 2. Hours of ventilation/day.combined the use of synthetic ketone bodies (D,L-3-OH butyrate) as an
alternative energy substrate for the heart, 2:1 ketogenic diet to reduce
glucose intake and high-protein diet to enhance gluconeogenesis.
After two years of treatment, echocardiography showed an improve-
ment of cardiomyopathy. Growth and liver size remained normal, and
no side effects were observed. These preliminary results of a case report
need conﬁrmation in larger series.
In adult patients themain problem is distal weakness that leads to a
chronic progressive myopathy leading to impaired ambulation. These
patients might develop a cardiomyopathy that however responds well
to appropriate drug therapy.
2.3. Glycogenosis type V (GSDV, myophosphorylase deﬁciency, McArdle
disease)
McArdle disease is due to the deﬁciency of the glycogenolytic
enzyme myophosphorylase. The disease is clinically characterized
by fatigue and exercise induced myalgia, and, in some cases, by epi-
sodic myoglobinuria with possible acute renal failure due to rhabdo-
myolysis. The typical morphological picture of muscle biopsy is the
subsarcolemmal blebs. Diagnosis can be done by histoenzymatic
stain for phosphorylase and the identiﬁcation of the most frequent
mutation in the PYGM gene, (the p.R50X stop codon mutation),
which is frequent from 30 to 50% of Caucasian mutant patients. A
small proportion of patients develops a progressive weakness of
proximal muscles, especially of the upper limbs [31,32]. No trial so
far has demonstrated efﬁcacy of any drug, dietary treatment or exer-
cise scheme, except aerobic training. One of the most interesting ap-
proaches is treatment with vitamin B6. In normal individuals the
skeletal muscle contains 80% of the total pool of vitamin B6 bound
as pyridoxal-phosphate (PLP) to muscle phosphorylase, playing a
crucial role for enzyme activity. In McArdle patients decreased
phosphorylase substantially diminishes PLP in skeletal muscle [33].
Recently, a Japanese patient was treated for more than 2 years with
vitamin B6 supplementation, demonstrating amelioration in symp-
toms, increase of enzymatic levels on muscle biopsy and increase
of lactate in response to effort during the grip test [34]. Along with
methodological limits (i.e. outcome measures, numerosity of cohort),
Sato et al. [34] postulated that the action of vitamin B6 supplementation
may require the presence of some residual muscle phosphorylase and
probably would have not be seen in patients with null mutations
(p.R50X). They hypothesize that vitamin B6 supplementation can re-
store some stability to the mutant enzyme and enhance the residual
phosphorylase activity in skeletal muscle, followed by improvement in
insufﬁcient anaerobic glycolysis of skeletal muscle. Apart from that,
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toms includes dietary treatment and physical training [35,36]. The
infusion of sucrose before exercise can markedly improve exercise tol-
erance probably by an increased availability of blood-borne glucose,
which partially rescues muscle oxidative metabolism early in exercise
in McArdle patients [37]. A carbohydrate rich diet seemsmore effective
than a high protein diet [38]. A regular aerobic training program can
potentially improve the metabolic capacity and the exercise tolerance
by conditioning muscles for oxidative phosphorylation. Moderate
aerobic exercise (30 min per day, 4 days a week, at an intensity corre-
sponding to 60–70% of maximal heart rate) was tested in 8 patients
for 3 months [39]. This trainingprogramwas safe and increased average
work capacity, oxygen uptake, cardiac output, and mitochondrial
enzyme levels without causing pain or cramps or increasing serum
creatine kinase (CK). The impact of the angiotensin-converting enzyme
(ACE) polymorphism on the disease was described in GSDV by
Martinuzzi et al. [40], who demonstrated a strong correlation between
the severe phenotype and the number of D alleles. A double-blind,
randomized, placebo-controlled trial involving 8 patients treated with
an ACE inhibitor (2.5 mg ramipril) demonstrated a signiﬁcant change
in disability score, even if it failed to show any treatment effect in the
objective measures of exercise performance and muscle metabolism
chosen as primary end-point for the overall McArdle population [41].
The treatment seemed to modify exercise physiology in D/D patients,
raising the possibility of a differential haplotype-linked sensitivity to
the treatment.
3. Lipid storage myopathies
3.1. Carnitine deﬁciency
Muscle carnitine deﬁciency syndrome was discovered in 1973 [42],
and systemic carnitine deﬁciency (SCD) was reported in 1975 [43].
We reported in 1980 the ﬁrst treated case of primary systemic
carnitine deﬁciency with SLC22A5 gene mutation [44]. During the
first years the child had several attacks of hypoketotic encephalopathy,
and cardiomyopathy was detected at the age of 3 years. Prompt
response to carnitine therapy was observed, as documented by echo-
cardiography and ECG. In primary SCD, studies of carnitine uptake in
cultured skin ﬁbroblasts show a defect in the speciﬁc high afﬁnity low
concentration active carrier (OCTN2) mediated carnitine transport sys-
tem. The free serum carnitine was low. Carnitine treatment with
100 mg/kg/day in a short time resulted in an improvement in strength
and somatic growth. However, the vulnerability of individuals with
carnitine deﬁciency and the need for careful cardiac vigilance is needed
to prevent morbidity and mortality.
3.1.1. Case report
This boy since the ﬁrst months of life presented motor incoordina-
tion, muscle weakness and effort intolerance. At the age of 3 years he
was recognized to present heart abnormality and echocardiographic
examination showed increased left ventricular volume. Clinical con-
dition worsened and at 7 years he presented dilated cardiomyopathy.
Muscle biopsy showed a lipid storage myopathy, muscle carnitine
was 3%; plasma carnitine was 8% of controls. Genetic analysis of the
SLC22A5 gene showed a homozygous missense mutation (c.1540CNT;
p.T440M). A cardiac transplantation was considered. He was treated
with ACE inhibitors, diuretics and carnitine supplementation with a
progressive improvement of heart condition. There was a decrease in
cardiac volume and increase of ejection fraction to 43%, and cardiac
transplantationwas avoided through supplementary carnitine treatment.
3.2. Neutral lipid storage disease with myopathy (NLSD-M)
Neutral lipid storage disease with myopathy is characterized by
either childhood or adult onset of slowly progressive proximal muscleweakness affecting the upper limbs and associated with increased
serum CK. In some cases, distal asymmetrical muscle weakness may
also occur. About half of patients develop cardiomyopathy later in the
disease course. Other variable features include diabetesmellitus, hepatic
steatosis, hypertriglyceridemia, and possibly sensorineural hearing loss.
Leukocytes show cytoplasmic accumulation of triglycerides (Jordan's
anomaly). Fischer et al. [45] described 3 affectedwomen, from3 families
of Dutch, French, and Algerian origin, who showed marked triglyceride
storage in muscle and delay in walking, variable cardiac abnormalities,
and hepatomegaly. Laboratory investigations revealed elevated levels
of serum transaminases and CK. These patients harbored mutations in
the PNPLA2 gene. PNPLA2 catalyzes the initial step in the breakdown
of intracellular triglycerides and, as expected, PNPLA2-defective patients
showed impaired degradation of cytoplasmic triglycerides.
3.2.1. Case report
This was a 44-year-old woman of Iranian origin, which was born
from consanguineous parents (ﬁrst degree cousins). She complained
for early fatigability since late teens followed by increasing difﬁculties
in running andwalking. After the age of 30, she developed a progressive
weakness in the upper and lower limb girdles with elevated CK levels
(1200 U/L). Besides elevated serum transaminases, laboratory tests
also revealed raised plasma levels of glucose, total triglycerides and
VLDL. She was a homozygous carrier for apoE2 allele and subsequent
laboratory tests conﬁrmed the presence of type 2 diabetes. In the fol-
lowing years she showed marked wasting of the lower girdle muscles,
with both proximal and distal leg weakness and less severe arm and
forearm weakness. Tendon reﬂexes were normal. The skin was not
affected. EMG showed a myopathic pattern. CT scan of the lower limb
muscles showed fatty replacement in the right gluteus extending to
the upper thigh with asymmetric distribution. An ultrasound of the
abdomen showed marked fatty liver. Echocardiography and measure-
ment of vital capacity were normal.
Muscle biopsy demonstrated marked neutral lipid storage with the
appearance of vacuolated ﬁbers and increased Oil-Red-O droplets espe-
cially in the atrophic ﬁbers (Fig. 3).
Total muscle carnitine was mildly reduced (8.5 nmol/mg non-
collagen proteins, normal 10.5–29.5). Peripheral blood leukocytes
showed the typical cytoplasmic lipid droplets called Jordan's anomaly.
She was found to be homozygous for a single base pair deletion at
position 695 (c.695delT), which resulted in a frame shift leading to a
premature stop codon (p.L255X) in the PNPLA2 gene [46]. This patient
had a relatively early-onset (third decade), with asymmetric progres-
sive weakness of upper and lower limbs. In several other NLSD-M
cases, both heart and diabetes have been reported whereas this patient
had no heart involvement but had type II diabetes. The treatment of the
disorder is still elusive, although a promising animal model is available,
but the complete lack of ATGL causes a severe and early lethal
phenotype in themouse, and therefore themousemodel can be consid-
ered only an extreme variant of the disease.
3.3. Electron transfer ﬂavoprotein (ETF) dehydrogenase or riboﬂavin-
responsive multiple acyl-CoA dehydrogenase deﬁciency (RR-MADD)
This disease is a rather unrecognized cause of lipid storagemyopathies
[47]. MADD is caused by defects in ETF or ETF-dehydrogenase (ETFDH),
two mitochondrial enzymes which contain ﬂavin adenine dinucleotide
as a prosthetic group. A defect of ETF and ETFDH can affect all dehydroge-
nases in fatty-acid beta-oxidation, such as long-chain, medium-chain and
short-chain acyl-CoA-dehydrogenases, and therefore carries the name of
multiple acyl-CoA dehydrogenase. The diagnosis is clinical but in
repeated biopsieswe have observed the increase in the previously absent
oxidative enzymes. Thedisease is characterized by glutaric aciduria type 2
in urine during crises and by lipid storage myopathy in muscle. The
phenotype is heterogeneous: late onset patients manifest proximal
myopathy, high CK levels, vomiting andhypoglycemia. Themeasurement
Fig. 3. Muscle biopsy from this patient with NLSD-M showing vacuolated ﬁbers (A) on
H&E stain and lipid droplet accumulation (B) by Oil-Red-O stain.
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is useful for diagnosis [48], since it reveals low free carnitine but elevated
acyl-carnitines. The disease appears well responsive to treatment, since
riboﬂavin (100–400 mg/d) alone or in combination with carnitine sup-
plementation can reverse the prominent weakness in few months and
normalize the deﬁciency [49]. Other cases have been treated also with
coenzyme-Q, which intervenes as a shuttle between complex II and
complex III.
3.3.1. Case report
This patientwas a 22 year old girlwhowas extremely thin andweak.
She presented with progressive lower limb weakness and exercise
intolerance after 2–3 months of metabolic crises. In the course of one
year, she presented recurrent episodes of hypoglycaemia (31 mg/dL),
vomiting and conspicuous loss of weight (10 kg), with high CK
(15,000 U/L) and myalgia. She had to be fed by a nasogastric tube and
became quadriplegic. On neurological examination she was able to
rise from lying to sitting position only with the help of hands, and she
had weakness of head ﬂexors, deltoids, biceps, and triceps bilaterally.
She had also weakness in lower limbs. She was unable to keep arms in
horizontal position or to raise legs from bed, presented winging
scapulae and hypotrophic muscles. From the initial period, her CK
decreased, but gamma-GT was constantly elevated. A muscle biopsy
was done and showed lipid storagemyopathywith carnitine deﬁciency:
total muscle carnitine was 4.34 (n.v. 10.5–29.5) with a rather high pro-
portion of acyl-carnitines; plasma carnitine was 6.77 (n.v. 36–72.9).
Echocardiography showed mitral prolapse and minimal reﬂux. Muscle
MRI showed hypotrophicmuscleswithmyoedema in upper girdlemus-
cles and in the legs. She was then treated with supplementary with
carnitine and riboﬂavin both orally and by infusion: with this treatment
she removed the nasogastric tube and started oral therapy. Her bodyweight increased. Genetic analysis of ETFDH gene showed one
homozygous mutation (c.1649TNG, p.L550P). Her sister, a 28 year
old plump woman, from the age of 4 years had a progressive history
of lower limb weakness; CK was 11,000 U/L and was diagnosed by a
rheumatologist as polymyositis; however, she did not respond to
various immuno-modulatory treatments (i.e. IVIg, methotrexate or
steroid) causing a cushingoid syndrome. On neurological examina-
tion she had slow gait, kyphoscoliosis, weakness in ﬂexor muscles
\and upper limbs. Muscle biopsy showed lipid storage and low muscle
carnitine 1.77 (n.v. 10.5–29.5). Plasma acyl-carnitines proﬁle was
normal. She was started on treatment with riboﬂavin and carnitine
with clinical improvement.
The take-home message is that MADD can be an under-recognized
entity; appropriatemetabolic or biochemical studiesmight help diagno-
sis in these metabolic myopathies, and identify possible treatments
leading to a prompt patients' response.
3.4. Carnitine palmitoyl transferase II (CPT-II) deﬁciency
CPT-II deﬁciency is due to a mitochondrial fatty acid oxidation
disorder, clinically characterized by cramps, myalgia, exercise intoler-
ance and episodes of myoglobinuria, usually triggered by prolonged
exercise, cold, fever, fasting or anesthetic drugs [50]. In a large series
of patients, Fanin et al. [51] divided molecularly deﬁned patients in
mild or severe according to the number of myoglobinuric episodes.
Patients affected by CPT-II deﬁciency usually can control their symp-
toms by avoiding triggering factors, and remain clinically stable
adopting appropriate lifestyle recommendation and a dietary treatment
with high carbohydrate doses [52]. Glucose infusion is of beneﬁt during
or after myoglobinuria, but oral glucose does not achieve the same
effects, probably because of its low penetration in muscle and because
of the insulin-response, which inhibits muscle glycogenolysis [53]. In
the recent years, new drugs have been tested to increase fatty acid
oxidation. Fibrates are a class of hypolipidemic drugs that increase
HDL-level by mRNA up-regulation of many lipid-metabolism genes via
the interaction with the steroid-thyroid transcription factor PPARalpha.
Recent studies demonstrated that bezaﬁbrate increases CPT2mRNAand
normalizes enzyme activity in mild form of CPT-II deﬁcient cultured
ﬁbroblasts and myoblasts [54]. A trial including 6 patients treated
with bezaﬁbrate was conducted in France: in this trial the primary
outcome was the level of fatty acid oxidation in muscle biopsies. A
normalization of fatty acid oxidation level was found in all patients,
due to a signiﬁcant increase in palmitoyl-L-carnitine oxidation,
increased CPT2 mRNA, and the enzyme protein. Furthermore, a
reduction of episodes of rhabdomyolysis, amelioration of quality of
life measured by SF-36, no adverse effects, an increase in physical
activity and a decline in muscular pain were reported [54,55].
Subsequent studies on CPT-II deﬁcient patients were not able to
conﬁrm the long-term efﬁcacy and safety of this therapy.
3.4.1. Case report
This is a 19 year-old man who after physical exercise experienced
severe weakness and pain in lower limbs, fever and myoglobinuria.
One year later, during febrile illness, he had another episode of
severe myalgia and weakness in the four limbs with myoglobinuria
and acute renal insufﬁciency, which required dialysis. At the age of
20 years neurological examination was negative, EMG was myo-
pathic and CK was normal. At the age of 44 years he complained
of several episodes of myoglobinuria following fever or physical
exercise; on neurological examination he had normal gait, slight
limitation in foot dorsiﬂexion and mild weakness in ﬁnger exten-
sors. He underwent muscle biopsy at the age of 21 years, which
showed some ﬁbers with small vacuoles and lipid droplet accumu-
lation. Biochemical assay of the activity of CPT-II enzyme in muscle
showed a severe reduction. Analysis of mutations in the CPT2 gene
Table 1
Spectrum of metabolic myopathies with new developments.
Disease Treatment Genetic diagnosis
GSDII ERT IVS1 mutation in GAA
GSDIII Dietary treatment Mutation in AGL
GSDV Oral glucose, high protein diet Common p.R50X mutation in PYGM
Primary carnitine deﬁciency Carnitine Mutations in SLC22A5
Neutral lipid storage disorder with myopathy (NLSD-M) No treatment Mutation in PNPLA2
Neutral lipid storage disorder with ichthyosis (NLSD-I) No treatment Mutation in CGI-58
Riboﬂavin responsive multiple acyl-CoA dehydrogenase deﬁciency (RR-MADD) Riboﬂavin Mutation in ETF-DH
CPT-II Myoglobinuria prevention Common p.S113L mutation in CPT2
620 C. Angelini / Biochimica et Biophysica Acta 1852 (2015) 615–621revealed a homozygous mutation which was reported to recur in
the Southern Italy.
4. Conclusions
With the advent of molecular genetics, many diagnoses are possible
with amolecular ormetabolic screening that is subsequently conﬁrmed.
Diagnosing patients with metabolic myopathies is rewarding for the
advent of numerous therapeutic strategies (Table 1) that can be used
in these disorders.
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